Cidara Therapeutics to Report Second Quarter 2025 Financial Results and Host Quarterly Conference Call on August 7, 2025
Rhea-AI Summary
Cidara Therapeutics (Nasdaq: CDTX), a biotechnology company specializing in drug-Fc conjugate (DFC) immunotherapies through its Cloudbreak® platform, has scheduled its second quarter 2025 financial results announcement for August 7, 2025.
The company will release its financial results and operational highlights after U.S. market close, followed by a conference call and webcast at 5:00 PM Eastern Time. Investors can access the call via U.S. toll-free (1-844-825-9789) or international (1-412-317-5180) numbers using Conference ID 10200740.
Positive
- None.
Negative
- None.
News Market Reaction – CDTX
In the trading session that priced this news, CDTX declined 3.13%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, July 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that it will report its second quarter 2025 financial results and operational highlights after the close of the U.S. financial markets on Thursday, August 7, 2025. The Company will host a conference call and webcast at 5:00 PM Eastern Time to discuss the results and provide an update on business operations.
Conference Call Dial-In & Webcast Information
| Date: | Thursday, August 7, 2025 |
| Time: | 5:00 PM Eastern Time |
| United States: | 1-844-825-9789 |
| International: | 1-412-317-5180 |
| Conference ID: | 10200740 |
| Webcast: | Link |
About Cidara Therapeutics
Cidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel drug-Fc conjugates (DFCs) comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment (Fc). Cidara’s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA), and the Company announced positive top-line results from its Phase 2b NAVIGATE clinical trial in June 2025. Additional DFCs have been developed for oncology and in July 2024 Cidara received IND clearance for CBO421 which is intended to target CD73 in solid tumors. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com
MEDIA CONTACT:
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com
